Diametric Capital’s BridgeBio Pharma BBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$555K Sell
8,435
-860
-9% -$67K 0.05% 342
2026
Q2
$692K Buy
+9,295
New +$651K 0.07% 283
2024
Q3
– Sell
-12,076
Closed -$306K – 380
2024
Q2
$306K Buy
+12,076
New +$330K 0.17% 176

Other funds holding BBIO

Diametric Capital's BBIO Position: Q3 2026 in Review

Diametric Capital reduced its BridgeBio Pharma (BBIO) stake by 9.3% in Q3 2026, selling an estimated $67K and leaving 8,435 shares worth $555K. The position accounts for 0.05% of the portfolio, ranked #342.

Diametric Capital first reported a position in BBIO in Q2 2024 and has held it in 3 quarters since. The position peaked at $692K in Q2 2026. 471 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Diametric Capital held 8,435 shares of BridgeBio Pharma worth $555K as of Q3 2026.
  • Diametric Capital sold 860 BridgeBio Pharma shares in Q3 2026, an estimated $67K.
  • BridgeBio Pharma made up 0.05% of Diametric Capital's portfolio in Q3 2026, its #342 holding.
  • Diametric Capital first reported a position in BridgeBio Pharma in Q2 2024 and has held it in 3 quarters since.
  • Diametric Capital's BridgeBio Pharma position peaked at $692K in Q2 2026.
  • 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Diametric Capital's 13F filing for Q3 2026, filed 16 Nov 2026.